Cargando…

Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment

BACKGROUND: (18)F-flortaucipir PET received FDA approval to visualize aggregated neurofibrillary tangles (NFTs) in brains of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD). However, manufacturer’s guidelines for visual interpretation of (18)F-flortaucipir PET d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Charles D., Ponisio, Maria Rosana, Lang, Jordan A., Flores, Shaney, Schindler, Suzanne E., Fagan, Anne M., Morris, John C., Benzinger, Tammie L.S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200228/ https://www.ncbi.nlm.nih.gov/pubmed/37092225 http://dx.doi.org/10.3233/JAD-230032

Ejemplares similares

Flortaucipir (tau) PET in LGI1 antibody encephalitis
por: Day, Gregory S., et al.
Publicado: (2021)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage
por: Meeker, Karin L., et al.
Publicado: (2022)

Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
por: Su, Yi, et al.
Publicado: (2018)

Optimizing quantification of MK6240 tau PET in unimpaired older adults
por: Harrison, Theresa M., et al.
Publicado: (2023)

Evaluation of a visual interpretation method for tau‐PET with (18)F‐flortaucipir
por: Sonni, Ida, et al.
Publicado: (2020)

Sex modulates the ApoE ε4 effect on brain tau deposition measured by (18)F-AV-1451 PET in individuals with mild cognitive impairment
por: Liu, Min, et al.
Publicado: (2019)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
por: Koychev, Ivan, et al.
Publicado: (2017)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Influences on PET Quantification and Interpretation
por: Rogasch, Julian M. M., et al.
Publicado: (2022)

Advancing Tau-PET quantification in Alzheimer’s disease with machine learning: introducing THETA, a novel tau summary measure
por: Gebre, Robel K., et al.
Publicado: (2023)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET
por: Goldhardt, Oliver, et al.
Publicado: (2019)

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition
por: Rauchmann, Boris Stephan, et al.
Publicado: (2021)

The Spatial Patterns and Determinants of Cerebrospinal Fluid Circulation in the Human Brain
por: Nazeri, Arash, et al.
Publicado: (2023)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Characteristics of Tau and Its Ligands in PET Imaging
por: Harada, Ryuichi, et al.
Publicado: (2016)

Longitudinal tau PET in ageing and Alzheimer’s disease
por: Jack, Clifford R, et al.
Publicado: (2018)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Predicting future rates of tau accumulation on PET
por: Jack, Clifford R, et al.
Publicado: (2020)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer's disease
por: Yan, Shaozhen, et al.
Publicado: (2020)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment
por: Schedin‐Weiss, Sophia, et al.
Publicado: (2020)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease
por: Cruchaga, Carlos, et al.
Publicado: (2010)

PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
por: James, Olga G., et al.
Publicado: (2015)

An autoradiographic evaluation of AV-1451 Tau PET in dementia
por: Lowe, Val J., et al.
Publicado: (2016)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
por: Rubinski, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bifkdfhs9cjj23aj7k2d2mi16g